Skip to content

Study · Non-randomized trial · n = 10 · 1996

3 results

Lanreotide inhibits human jejunal secretion induced by prostaglandin E1 in healthy volunteers.

Sobhani I, René E, Ramdani A, Bayod F, Sabbagh LC, Thomas F, Mignon M

British journal of clinical pharmacology1 Feb 1996Cited by 8 (Europe PMC)

PMID8838436 (opens in a new tab)DOI10.1111/j.1365-2125.1996.tb00167.x (opens in a new tab)PepBankPUB-08838436
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, lanreotide significantly reduced the PGE1-induced jejunal secretion response involving water, sodium, potassium, and chloride compared with the control period.

    In plain wordsIn healthy volunteers, lanreotide reduced stimulated intestinal water and electrolyte secretion compared with the control period.

    Peptide
    Lanreotide
    Outcome
    DecreasePGE1-induced jejunal water and electrolyte secretion
    Study

    n = 10

    Comparator
    Control period
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    In healthy volunteers, PGE1 induced secretion of H2O, Na+, K+ and Cl- in the jejunum and lanreotide reduced significantly PGE1-induced response.
    3 context sentences
    Summary · context
    Accordingly, 10 healthy volunteers (age 18-35 years, mean 27) and two patients with AIDS (26 and 33 years) suffering from water diarrhoea (> 800 ml day-1) underwent intestinal perfusion using a four lumen tube with proximal occluding balloon.
    Summary · context
    The effect of intravenous lanreotide on the jejunal PGE1-induced secretions of water and electrolytes was analysed in healthy subjects and on the basal secretions in AIDS patients.
    Summary · context
    The antisecretory effect of lanreotide was evaluated in each subject as the difference between fluxes compared to the control period.
  2. 02HumanNon-randomized trialEfficacy outcome

    In AIDS patients with watery diarrhea, lanreotide reduced basal jejunal water flux in a dose-dependent manner compared with the control period.

    In plain wordsIn AIDS patients with watery diarrhea, lanreotide reduced intestinal water flux compared with the control period, with a dose-dependent effect.

    Peptide
    Lanreotide
    Outcome
    DecreaseBasal jejunal water flux
    Study

    n = 2

    Comparator
    Control period
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    In both AIDS patients basal fluxes of water and ions were reduced by lanreotide in a dose-dependent manner.
    3 context sentences
    Summary · context
    Accordingly, 10 healthy volunteers (age 18-35 years, mean 27) and two patients with AIDS (26 and 33 years) suffering from water diarrhoea (> 800 ml day-1) underwent intestinal perfusion using a four lumen tube with proximal occluding balloon.
    Summary · context
    The effect of intravenous lanreotide on the jejunal PGE1-induced secretions of water and electrolytes was analysed in healthy subjects and on the basal secretions in AIDS patients.
    Summary · context
    The antisecretory effect of lanreotide was evaluated in each subject as the difference between fluxes compared to the control period.
  3. 03HumanNon-randomized trialEfficacy outcome

    In AIDS patients with watery diarrhea, lanreotide reduced basal jejunal ion flux in a dose-dependent manner compared with the control period.

    In plain wordsIn AIDS patients with watery diarrhea, lanreotide reduced intestinal ion flux compared with the control period, with a dose-dependent effect.

    Peptide
    Lanreotide
    Outcome
    DecreaseBasal jejunal ion flux
    Study

    n = 2

    Comparator
    Control period
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    In both AIDS patients basal fluxes of water and ions were reduced by lanreotide in a dose-dependent manner.
    3 context sentences
    Summary · context
    Accordingly, 10 healthy volunteers (age 18-35 years, mean 27) and two patients with AIDS (26 and 33 years) suffering from water diarrhoea (> 800 ml day-1) underwent intestinal perfusion using a four lumen tube with proximal occluding balloon.
    Summary · context
    The effect of intravenous lanreotide on the jejunal PGE1-induced secretions of water and electrolytes was analysed in healthy subjects and on the basal secretions in AIDS patients.
    Summary · context
    The antisecretory effect of lanreotide was evaluated in each subject as the difference between fluxes compared to the control period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.